

MAY 03 2005

Sheet 1 of 2

FORM PT 61449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

APPLICATION NO.:

OC01617K1

10/776, 988

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

APPLICANT:  
Timothy J. Guzi et al.

FILING DATE:  
02/11/2004

GROUP

1622

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
✓	AA	5,571,813	11/05/1996	Rühter et al.			
	AB	5,602,136	02/11/1997	Rühter et al.			
	AC	5,602,137	02/11/1997	Rühter et al.			
	AD	5,688,949	11/18/1997	Inoue et al.			
	AE	5,707,997	01/13/1998	Shoji et al.			
	AF	5,919,815	07/06/1999	Bradley et al.			
	AG	6,040,321	03/21/2000	Kim et al.			
	AH	6,107,305	08/22/2000	Misra et al.			
	AI	6,191,131	02/20/2001	He et al.			
	AJ	6,262,096	07/17/2001	Kim et al.			
	AK	6,413,974	07/02/2002	Dumont et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
✓	AL	DE 102 23 917 A1	11/12/2003	Germany			
	AM	EP 0 628 559	04/03/2002	Europe			
	AN	EP 1 334 973	08/13/2003	Europe			
	AO	WO 02/22610	03/21/2002	PCT			
	AP	WO 02/40485	05/23/2002	PCT			
	AQ	WO 02/50079	06/27/2002	PCT			
	AR	WO 03/091256 A1	11/06/2003	PCT			
	AS	WO 95/35298	12/28/1995	PCT			


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	AT	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224: 771-786.
	AU	Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", <i>Journal of Medical Chemistry</i> , (2002), 45: 3905-3927.
	AV	Melley et al., "Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects", <i>J. Med. Chem.</i> (2003), 46(2): 222-236.
	AW	Novinson et al., "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-a]pyrimidines", <i>J. Med. Chem.</i> (1977), 20(2): 288-299.
	AX	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16(9): 2986-2999.
✓	AY	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243:527-536.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: <b>OC01617K1</b>	APPLICATION NO.: <b>10/776,988</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT: <b>Timothy J. Guzi et al.</b>	
				FILING DATE: <b>02/22/2004</b>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
<input checked="" type="checkbox"/>	AZ	Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57: 3375-3380.			
<input type="checkbox"/>	BA	Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-a]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), 47(7): 928-938.			
<input type="checkbox"/>	BB	Translation of WO 03/91256, <i>A Rising Sun Communications Ltd. Translation Product</i> , (1-62)			
<input type="checkbox"/>	BC	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-a]pyrimidines.", <i>Chem. Pharm. Bull.</i> (1962), 10: 620-626.			
<input type="checkbox"/>	BD	Cai et al., "5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, Systemically Active and Broad Spectrum Antagonists for NMDA/glycine, AMPA, and Kainate Receptors", <i>J. Med. Chem.</i> (1997), 40:3679-3686.			
<input type="checkbox"/>	BE	Bruce L. Finkelstein, "Regioselective Lithiation and Reaction of [1,2,4]Triazolo[1,5-a]pyridine and Pyrazolo[1,5-a]pyridine", <i>J. Org. Chem.</i> , (1992), 57: 5538-5540.			
<input type="checkbox"/>	BF	Ongkeko et al., "Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage", <i>Journal of Cell Science</i> (1995), 108: 2897-2904.			
<input type="checkbox"/>	BG	Shiota et al., "Regioselective Reactions of Organozinc Reagents with 2,4-Dichloroquinoline and 5,7-Dichloropyrazolo[1,5-a]pyrimidine", <i>J. Org. Chem.</i> (1999), 64: 453-457.			
<input checked="" type="checkbox"/>	BH	Novinson et al., "Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo- $\alpha$ -triazines <sup>1</sup> ", <i>Journal of Medicinal Chemistry</i> , (1976), 19(4): 517-520.			
<input type="checkbox"/>	BI				
EXAMINER		DATE CONSIDERED			
		6/17/05			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					